- Home
- MBRX vs CMMB Comparison
MBRX vs CMMB Comparison
Compare MBRX & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBRX | CMMB |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1M | 11.2M |
| IPO Year | 2016 | 2023 |
Fundamental Metrics
Financial Performance| Metric | MBRX | CMMB |
|---|---|---|
| Price | $2.36 | $1.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $61.00 | $25.00 |
| AVG Volume (30 Days) | ★ 258.5K | 43.0K |
| Earning Date | 05-12-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $45.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.87 |
| 52 Week High | $7.98 | $3.86 |
Technical Indicators
Market Signals| Indicator | MBRX | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 48.11 | 47.68 |
| Support Level | $2.16 | $1.48 |
| Resistance Level | $2.64 | $1.89 |
| Average True Range (ATR) | 0.20 | 0.17 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 22.79 | 30.27 |
Price Performance
Historical ComparisonAbout MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.